CLINFAN Szolgáltató Kft

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis7 trials
• Crohn's disease3 trials
• Obesity2 trials

Phase

• Phase 38 trials
• Phase 22 trials

Status

• Active, not recruiting4 trials
• Completed4 trials
• Recruiting2 trials

Lead sponsor

• Eli Lilly and Company6 trials
• AbbVie1 trial
• Gilead Sciences Inc.1 trial
• Pfizer1 trial
• Polpharma Biologics S.A.1 trial

Running trials

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

  Contact: Agnes Salamon (principal investigator)

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

  Contact: Agnes Salamon (principal investigator)

• Active, not recruiting

  Study of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis

  2022-501119-14-01· Phase 2· Gilead Sciences Inc.· Source

• Active, not recruiting

  Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

  NCT04524611· Phase 3· AbbVie· Source

• Active, not recruiting

  A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

  NCT04232553· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

  NCT03519945· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity2 recruiting
• Crohn's disease1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and how safe it is compared to a licensed treatment called Entyvio®.

  2022-502778-18-00· Phase 3· Polpharma Biologics S.A.· Source

• Completed

  Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis

  NCT04607837· Phase 2· Pfizer· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Eli Lilly and Company· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source